Patients on dopamine medication showed partial recovery of brain-heart coupling, correlating with reduced motor symptoms.
Patients largely reported independence and good quality of life in the first decade of the disease. Younger onset age correlated with slower progression of overall, motor, and non-motor symptoms. Females exhibited better overall motor and non-motor scores compared to males.
Participants showed faster responses in congruent trials compared to incongruent trials, with GPi activity being critical for cognitive processing during conflict tasks, suggesting effective modulation of cognitive control through DBS.
Clinical outcomes showed a 46% improvement in UPDRS III scores and a 32% improvement in PDQ39 scores, indicating significant enhancement in motor function and quality of life.
Levodopa improved mean tap amplitude and stride length during fast tapping in Parkinson's disease participants, indicating enhanced motor performance in both upper limb and gait tasks.
The study found that mean pain scores significantly improved after STN DBS, with a more dorsal active contact location being the only significant predictor of pain improvement. The stimulation locus for maximal pain improvement was identified as being lateral, anterior, and dorsal to that for maximal motor improvement.
The study found that early-stage Parkinson's disease patients exhibited partial preparatory suppression, while those in later stages lacked it completely. Dopamine medication reduced raw corticospinal excitability but did not restore preparatory suppression, indicating a complex relationship between dopamine levels and motor control.
Patients with high dopaminergic responses exhibited more integrated brain states during treatment, indicating better connectivity and potentially improved motor function. Lower dFNC in low responders correlated with poorer motor response.
The study found that structural integrity of the locus coeruleus correlates with response inhibition performance. Improved understanding of this relationship may lead to better-targeted treatments for impulsivity in Parkinson's disease and progressive supranuclear palsy.
DBS has been shown to improve motor symptoms, enhance quality of life, and increase the ability to perform daily activities in patients with Parkinson's disease.
The findings reveal that DBS and medication have differential effects on various resting state networks (RSNs), which is important for understanding their complementary treatment effects and potential side effects.
Increased streaming hours were associated with better verbal memory and lower irritability, indicating that cognitive and emotional factors significantly influence participation in the study.
The use of low-dose ketamine during DBS surgery resulted in satisfactory microelectrode recordings, maintained patient cooperation during stimulation testing, and preserved lead placement accuracy, suggesting an improved patient experience without compromising surgical effectiveness.
The mean UPDRS score decreased from 43.25 to 40, indicating improvement in motor symptoms. Cognitive function, walking and balance, postural stability, and constipation also showed significant improvements. The mean constipation severity score decreased from 3 to 1.75, and serum creatinine kinase levels decreased, with normalization of blood glucose and lipid levels.
While the MI-NF group did not show significant NF regulation or differences in imaging or clinical outcomes compared to the control group, both groups reported subjective improvements in kinesthetic body awareness. There was a significant improvement in motor function scores in both groups, which correlated with NF regulation of the right insula-dmFC connectivity in the MI-NF group.
The treatment improved response inhibition in hypersexual Parkinson's disease patients when exposed to sexual cues, indicating a potential therapeutic avenue for impulse control disorders.
At 6-12 months post-DBS, there was a median reduction of 440.5 mg/day in levodopa-equivalent daily dosage (LEDD), with 42.2% of patients achieving a reduction of ≥50% and 69.8% achieving a reduction of ≥30%. Early-onset and short-duration PD patients showed larger reductions in LEDD.
Participants in the virtual dance programs reported improvements in mood and emotional well-being, suggesting that these online classes can effectively modulate mood similar to in-person classes. The programs also provided a sense of community and support during a time of increased social isolation due to COVID-19.
DBS led to significant improvements in the amplitude and frequency of hand movements, as indicated by negative correlations with MDS-UPDRS-III scores for both right and left hand grasping.
Clinical outcomes improved significantly at six months post-surgery, with a reduction in levodopa-equivalent daily dosages. However, gait parameters such as step time asymmetry and phase coordination index showed increased asymmetry post-treatment, especially in the postural instability and gait disorder subgroup.
Propranolol significantly reduced tremor power and tremor-related activity in the motor cortex compared to placebo, irrespective of cognitive load.
Both STN and GPi DBS resulted in comparable improvements in motor symptoms, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS-III).
Improvement in muscle strength, coordination, balance, and overall quality of life for individuals with early onset Parkinson's disease, as well as enhanced psychosocial status.
Doxycycline treatment resulted in a significant reduction in the UDysRS total score and decreased ON time with troublesome dyskinesia, indicating an improvement in LID without worsening parkinsonism.
Prosaccade latencies were faster, and the saccadic main sequence was normalized, indicating improved saccade performance.
Participants showed improvements in quality of life and motor symptoms. Notably, PD patients experienced an increase in social satisfaction over time, while caregivers reported changes in their social role satisfaction. The intervention also promoted social cohesion and movement skills among participants.
The systematic review aims to assess the effectiveness of acupuncture in relieving fatigue and improving functional outcomes in patients with Parkinson's disease, highlighting its potential benefits in enhancing quality of life.
Cannabis users reported using it primarily for PD symptoms, with significant use for non-motor symptoms such as anxiety (45.5%), pain (44.0%), and sleep disorders (44.0%). Users were more likely to report insufficient control of their non-motor symptoms with prescription medications compared to non-users.
Expected positive outcomes include improved mitochondrial function in skin fibroblasts, enhanced motor function, quality of life, sleep quality, cognitive aspects, and humor in patients with PD.
Patients on dopaminergic medication showed significantly less avoidance of cognitively demanding tasks compared to when they were off medication, indicating increased motivation to exert cognitive control.
Patients with PD showed significant deficits in motor skill retention compared to neurologically intact individuals, particularly in sensory motor and visuomotor tasks. However, these deficits were reduced with augmented feedback and additional practice, indicating potential for improvement in motor rehabilitation.
After 8 weeks of treatment, PD patients receiving resistant starch showed a significant increase in fecal butyrate concentrations and a significant decrease in fecal calprotectin levels, indicating reduced intestinal inflammation. Clinically, there was a reduction in the load of non-motor symptoms in the PD + RS group.
MICT showed a significant improvement in Beck Depression Inventory scores compared to the control group, indicating a positive effect on mood symptoms. HIIT did not show significant improvements in mood compared to the control group.
The review indicates that MI can lead to significant improvements in motor function, particularly in balance and gait, with an 85.2% improvement in the Timed Up and Go (TUG) test with a cognitive task. Other improvements include a 5.8% enhancement in TUG and a 5.1% increase in walking speed.
The study found that participation in the Parkinson ECHO program significantly increased clinician confidence levels in diagnosing and managing Parkinson's disease, particularly among those serving rural and medically underserved communities.
The study aims to improve patient activation, quality of life, and clinical/functional measures through the use of the SIDERA^B system compared to usual care.
The study found potential evidence of differences in mRNA expression of the KTN1 gene in the putamen and substantia nigra between Parkinson's disease patients and healthy individuals, indicating a possible link to disease susceptibility.
The MEX-PD network has registered 262 PD patients and 302 controls, contributing to a better understanding of PD in the Mexican population. The study aims to identify genetic and environmental factors influencing PD outcomes, which may lead to improved quality of life and personalized treatments.
Reduction in levodopa equivalent daily dose (LEDD) was observed in 6 out of 8 patients, and total electrical energy delivered (TEED) increased in 4 out of 6 patients, suggesting some positive treatment outcomes.
The study aims to improve health outcomes for people with Parkinson's disease, enhance the quality of care experienced by patients and caregivers, and improve the work-life balance for healthcare professionals.
Task performance on the Anticipatory Response Inhibition Task and Balloon Analogue Risk Task can predict the severity of impulse control behaviors in patients with Parkinson's disease on dopamine agonist medication.
The study highlights the potential of neuroinflammation as a therapeutic target, suggesting that addressing this mechanism may improve disease monitoring and lead to the identification of novel druggable targets for Parkinson's disease.
Identifying risk factors such as pRBD, age, duration of diagnosis, impairment in daily activities, mild constipation, and antidepressant use can aid in the early detection of depression in Parkinson's disease patients, potentially leading to better management and outcomes.
Identifying altered functional connectivity in the cortico-striatal networks may help differentiate between the behavioral characteristics of patients with ICD and DDS, potentially guiding future neuromodulation therapies.